[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334701-105":59,"doc-detail-334701-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","the-potential-role-of-precision-medicine-to-alleviate-racial-disparities-in-prostate-bladder-and-renal-urological-cancer-care","The potential role of precision medicine to alleviate racial disparities in prostate, bladder and renal urological cancer care","","Racial disparities in oncological outcomes linked to social determinants of health (SDOH) and tumour biology are well documented for prostate cancer, yet similar inequities affect bladder and renal cancers. Precision medicine (PM) seeks personalized treatment grounded in individual patient characteristics and may help reduce these gaps across genito-urinary (GU) malignancies. The review summarizes evidence on racial disparities in GU cancers and evaluates studies where PM improved outcomes among racially diverse populations, drawing attention to unmet needs in trial representation and biology-driven tailoring.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-potential-role-of-precision-medicine-to-alleviate-racial-disparities-in-prostate-bladder-and-renal-urological-cancer-care/334701/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-potential-role-of-precision-medicine-to-alleviate-racial-disparities-in-prostate-bladder-and-renal-urological-cancer-care/334701.png","ImageObject",300,407,{"name":92,"@type":93},"Ava Thompson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",17,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem does precision medicine aim to address in GU cancers?","Question",{"text":113,"@type":114},"Precision medicine aims to personalize treatment using individual patient characteristics, with the potential to reduce racial inequities in prostate, bladder, and renal cancer care outcomes.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What evidence sources were used to gather the review?",{"text":118,"@type":114},"Evidence was obtained from PubMed and Web of Science using keywords covering prostate, bladder, and renal cancers, racial disparity, and precision medicine.",{"name":120,"@type":111,"acceptedAnswer":121},"Why is minority recruitment into clinical trials emphasized?",{"text":122,"@type":114},"The review notes the historical underrepresentation of ethnic minorities in clinical trials persists, and argues that urgent recruitment strategies are needed so PM benefits can be realized without limitations.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},334701,1790106047,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":4},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","DOI: 10.1002/bco2.323  \nREVIEW  \nThe potential role of precision medicine to alleviate racial disparities in prostate, bladder and renal urological cancer care  \nKunal K. Sindhu 1 | Zachary Dovey 2  | Marcher Thompson 3 |  \nAnthony D. Nehlsen 1 | Karin A. Skalina 4  | Beata Malachowska 4 | Shaakir Hasan 4 | Chandan Guha 4 | Justin Tang 4 | Lucas Resende Salgado 1  \n1Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA  \n2Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA 3Department of Radiation Oncology, AIS Cancer Center/Adventist Health, Bakersfield, CA, USA  \n4Department of Radiation Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA  \nCorrespondence  \nZachary Dovey, Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.  \nEmail: [zachdovey@gmail.com](zachdovey@gmail.com)  \nFunding information  \nNo outside funding was utilized in the writing of this research article.  \nAbstract  \nBackground: Racial disparities in oncological outcomes resulting from differences in social determinants of health (SDOH) and tumour biology are well described in prostate cancer (PCa) but similar inequities exist in bladder (BCa) and renal cancers (RCCs) . Precision medicine (PM) aims to provide personalized treatment based on individual patient characteristics and has the potential to reduce these inequities in GU cancers.  \nObjective: This article aims to review the current evidence outlining racial disparities in GU cancers and explore studies demonstrating improved oncological outcomes when PM is applied to racially diverse patient populations.  \nEvidence acquisition: Evidence was obtained from Pubmed and Web of Science using keywords prostate, bladder and renal cancer, racial disparity and precision medicine. Because limited studies were found, preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines were not applied but rather related articles were studied to explore existing debates, identify the current status and speculate on future applications.  \nResults: Evidence suggests addressing SDOH for PCa can reverse racial inequities in oncological outcomes but differences in incidence remain. Similar disparities in BCa and RCC are seen, and it would be reasonable to suggest achieving parity in SDOH for all races would do the same. Research applying a PM approach to different ethnicities is lacking although in African Americans (AAs) with metastatic castrateresistant prostate cancer (mCRPCa) better outcomes have been shown with androgen receptor inhibitors, radium-223 and sipuleucel. Exploiting the abscopal effect with targeted radiation therapy (RT) and immunotherapy has promise but requires further study, as does defining actionable mutations in specific patient groups to tailor treatments as appropriate.  \nConclusion: For all GU cancers, the historical underrepresentation of ethnic minorities in clinical trials still exists and there is an urgent need for recruitment strategies to address this. PM is a promising development with the potential to reduce  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2024 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company.  \ninequities in GU cancers, however, both improved understanding of race-specific tumour biology, and enhanced recruitment of minority populations into clinical trials are required. Without this, the benefits of PM will be limited.  \nKEYW OR DS  \ngenito-urinary cancers, precision medicine, racial disparity, social determinants of health, trial recruitment, tumour biology  \n1 | INTRODUCTION  \nAccording to CDC statistics, in the United States, over 300 000 urological cancers have been diagnosed each year since 2013, and 1 i","cbCaiubNqdac40cR","https://ap.wps.com/l/cbCaiubNqdac40cR","pdf",1817349,21,"English","# Introduction\n## Prostate cancer\n# Racial disparities in genitourinary cancers\n## Prostate cancer","[{\"question\":\"What problem does precision medicine aim to address in GU cancers?\",\"answer\":\"Precision medicine aims to personalize treatment using individual patient characteristics, with the potential to reduce racial inequities in prostate, bladder, and renal cancer care outcomes.\"},{\"question\":\"What evidence sources were used to gather the review?\",\"answer\":\"Evidence was obtained from PubMed and Web of Science using keywords covering prostate, bladder, and renal cancers, racial disparity, and precision medicine.\"},{\"question\":\"Why is minority recruitment into clinical trials emphasized?\",\"answer\":\"The review notes the historical underrepresentation of ethnic minorities in clinical trials persists, and argues that urgent recruitment strategies are needed so PM benefits can be realized without limitations.\"}]","The potential role of precision medicine to alleviate racial disparities in prostate, bladder and renal urological cancer care | PDF",1790007956,53]